Table 1 The 765 NPC patients with general clinical features and the correlation between pre-NLR and pre-PLR groups.

From: Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study

Characteristics

Total (%)

pre-NLR (%)

p-Value

pre-PLR (%)

p-Value

Low (n = 484)

High (n = 281)

 

Low (n = 446)

High (n = 319)

Gender

   

0.548

  

0.007*

 Male

573 (74.9)

366 (75.6)

207 (73.7)

 

350 (78.5)

223 (69.9)

 

 Female

192 (25.1)

118 (24.4)

74 (26.3)

 

96 (21.5)

96 (30.1)

 

Age (years old)

   

0.870

  

0.325

 < 47

370 (48.4)

233 (48.1)

137 (48.8)

 

209 (46.9)

161 (50.5)

 

 ≥ 47

395 (51.6)

251 (51.9)

144 (51.2)

 

237 (53.1)

158 (49.5)

 

8th T stage

   

0.002*

  

 < 0.001*

 T1-T2

133 (17.4)

101 (20.9)

32 (11.4)

 

96 (21.5)

37 (11.6)

 

 T3

308 (40.2)

191 (39.5)

117 (41.6)

 

185 (41.5)

123 (38.6)

 

 T4

324 (42.4)

192 (39.6)

132 (47.0)

 

165 (37.0)

159 (49.8)

 

8th N stage

   

0.778

  

0.192

 N0-N1

213 (27.8)

139 (28.7)

74 (26.3)

 

126 (28.3)

87 (27.3)

 

 N2

432 (56.5)

270 (55.8)

162 (57.7)

 

259 (58.1)

173 (54.2)

 

 N3

120 (15.7)

75 (15.5)

45 (16.0)

 

61 (13.6)

59 (18.5)

 

8th Clinical stage

   

0.043*

  

 < 0.001*

 I-II

37 (4.8)

29 (6.0)

8 (2.8)

 

29 (6.5)

8 (2.5)

 

 III

323 (42.3)

212 (43.8)

111 (39.5)

 

210 (47.1)

113 (35.4)

 

 IVa

405 (52.9)

243 (50.2)

162 (57.7)

 

207 (46.4)

198 (62.1)

 

ECOG

   

0.004*

  

0.004*

 0

566 (74.0)

375 (77.5)

191 (68.0)

 

347 (77.8)

219 (68.7)

 

 1

199 (26.0)

109 (22.5)

90 (32.0)

 

99 (22.2)

100 (31.3)

 

Pathological type

   

 < 0.001*

  

0.008*

 NKUC

743 (97.1)

478 (98.8)

265 (94.3)

 

440 (98.6)

303 (95.0)

 

 NKDC

14 (1.8)

2 (0.4)

12 (4.3)

 

3 (0.7)

11 (3.4)

 

 KSCC

8 (1.1)

4 (0.8)

4 (1.4)

 

3 (0.7)

5 (1.6)

 

Smoking

   

0.232

  

0.124

 No

516 (67.5)

319 (65.9)

197 (70.1)

 

291 (65.2)

225 (70.5)

 

 Yes

249 (32.5)

165 (34.1)

84 (29.9)

 

155 (34.8)

94 (29.5)

 

Drinking

   

0.899

  

0.388

 No

638 (85.6)

415 (85.7)

240 (85.4)

 

386 (86.5)

269 (84.3)

 

 Yes

110 (14.4)

69 (14.3)

41 (14.6)

 

60 (13.5)

50 (15.7)

 

Treatment

   

0.812

  

0.105

 IMRT

43 (5.6)

29 (6.0)

14 (5.0)

 

28 (6.3)

15 (4.7)

 

 CCRT

220 (28.8)

137 (28.3)

83 (29.5)

 

139 (31.2)

81 (25.4)

 

 CCRT + IC/AC

502 (65.6)

318 (65.7)

184 (65.5)

 

279 (62.5)

223 (69.8)

 

pre-HGB

   

 < 0.001*

  

 < 0.001*

 < 120 g/L

212 (27.7)

97 (20.0)

115 (40.9)

 

67 (15.0)

145 (45.5)

 

 ≥ 120 g/L

553 (72.3)

387 (80.0)

166 (59.1)

 

379 (85.0)

174 (54.5)

 

pre-ALB

   

0.002*

  

0.004*

 < 43 g/L

354 (46.3)

203 (41.9)

151 (53.7)

 

187 (41.9)

167 (52.4)

 

 ≥ 43 g/L

411 (53.7)

281 (58.1)

130 (46.3)

 

259 (58.1)

152 (47.6)

 

pre-LMR

   

 < 0.001*

  

 < 0.001*

 < 2.82

374 (48.9)

188 (38.8)

186 (66.2)

 

154 (34.5)

220 (69.0)

 

 ≥ 2.82

391 (51.1)

296 (61.2)

95 (33.8)

 

292 (65.5)

99 (31.0)

 

pre-CRP

   

 < 0.001*

  

 < 0.001*

 < 10 mg/L

554 (72.4)

384 (79.3)

170 (60.5)

 

350 (78.5)

204 (63.9)

 

 ≥ 10 mg/L

211 (27.6)

100 (20.7)

110 (39.5)

 

96 (21.5)

115 (36.1)

 
  1. NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, ECOG Eastern Cooperative Oncology Group, IMRT intensity modulated radiotherapy, CCRT concurrent chemoradiotherapy, IC induction chemotherapy, AC adjuvant chemotherapy, NKUC undifferentiated non-keratinizing carcinomas, NKDC differentiated non-keratinizing carcinomas, KSCC keratinizing squamous cell carcinoma, HGB hemoglobin, ALB albumin, CRP C-reactive protein, pre pretreatment.
  2. *Indicates a significant difference among groups with p < 0.05.
Back to article page